Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 1146-1149

  Endtz, Hubert P ^a   Mouton, Johan W ^a   Den Hollander, Jan G ^a   Van Den Braak, Nicole ^a   Verbrugh, Henri A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; FLUCLOXACILLIN; OFLOXACIN; PEFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TEICOPLANIN; TROVAFLOXACIN; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; COLONY FORMING UNIT; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 0031001953     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.1146     Document Type: Article

References (30)

1. Barry, A. L., and P. C. Fuchs. 1991. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob. Agents Chemother. 35:955-960.
2. Barry, A. L., S. D. Brown, and P. C. Fuchs. 1996. In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin (CP-99,219). J. Antimicrob. Chemother. 38:324-327.
3. Bourgault, A. M., W. R. Wilson, and J. A. Washington II. 1979. Antimicrobial susceptibilities of species of viridans streptococci. J. Infect. Dis. 140: 316-324.
4. Carratala, J., F. Alcaide, A. Fernandez-Sevilla, X. Corbella, J. Linares, and F. Gudiol. 1995. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin. Infect. Dis. 20:1169-1173.
5. Chin, N. X., V. M. Figueredo, A. Novelli, and H. C. Neu. 1988. In vitro activity of temafloxacin, a new difluoroquinolone antimicrobial agent. Eur. J. Clin. Microbiol. Infect. Dis. 7:58-63.
6. Coque, T. M., K. V. Singh, and B. E. Murray. 1996. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against Gram-positive cocci. J. Antimicrob. Chemother. 37:1011-1016.
7. Cormican, M. G., and R. N. Jones. 1996. In-vitro activity of trovafloxacin (CP99,219) tested by two methods against 150 vancomycin-resistant enterococcal isolates. J. Antimicrob. Chemother. 37:847-849.
8. Doern, G. V., M. J. Ferraro, A. B. Brueggemann, and K. L. Ruoff. 1996. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob. Agents Chemother. 40:891-894.
9. Domagala, J. M. 1994. Structure-activity and structure-side-etfect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 33:685-706.
10. Dworkin, R. J., B. L. Lee, M. A. Sande, and H. F. Chambers. 1989. Treatment of right-sided staphylococcal endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet ii:1071-1073.
11. Eliopoulos, G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37:366-370.
12. Entenza, J. M., M. Blatter, M. P. Glauser, and P. Moreillon. 1994. Parenteral sparfloxacin compared with ceftriaxone in the treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci. Antimicrob. Agents Chemother. 38:2683-2688.
13. Giamarellou, H. 1995. Activity of quinolones against Gram-positive cocci: clinical features. Drugs 49(Suppl. 2):58-66.
14. Gomez-Jimenez, J., E. Ribera, B. Almirante, O. Del Valle, A. Pahissa, and J. M. Martinez-Vasquez. 1989. Ciprofloxacin resistance and staphylococcal endocarditis. Lancet ii.1525-1526.
15. Gootz, T. D., K. E. Brighry, M. R. Anderson, B. J. Schmieder, S. L. Haskell, J. A. Sutcliffe, M. J. Castaldi, and P. R. McGuirk. 1994. In-vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial. Diang. Microbiol. Infect. Dis. 19:235-243.
16. Gootz, T. D., R. Zaniewski, S. Haskell, B. Schmieder, J. Tankovic, D. Girard, P. Courvalin, and R. J. Polzer. 1996. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob. Agents Chemother. 40:2691-2697.
17. Guiot, H. F. L., L. J. A. Corel, and J. M. J. J. Vossen. 1994. Prevalence of penicillin-resistant viridans streptococci in healthy children and in patients with malignant hematological disorders. Eur. J. Clin. Microbiol. Infect. Dis. 13:645-650.
18. Gutschik, E. 1996. The worldwide increase of antimicrobial resistance in oral streptococci challenges the recent recommendations of endocarditis prophylaxis, abstr. S22-04, p. 85. In Program and abstracts of the 4th International Conference on the Prevention of Infection. Nice, France.
19. Heldman, A. W., T. V. Hartert, S. C. Ray, E. G. Daoud, T. E. Kowalski, V. J. Pompili, S. D. Sisson, W. C. Tidmore, K. A. vom Eigen, S. N. Goodman, P. S. Lietman, B. G. Petty, and C. Flexner. 1996. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized compared with parenteral therapy. Am. J. Med. 101:68-76.
20. Hussain Qadri, S. M., and Y. Ueno. 1996. Antibacterial activity of trovafloxacin against Gram-positive blood culture isolates from nosocomial infections. Eur. J. Clin. Microbiol. Infect. Dis. 15:694-696.
21. Kloos, W. E., and T. L. Bannerman. 1995. Staphylococcus and Micrococcus, p. 282-298. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
22. Moellering, R. C., Jr. 1993. Quinolone antimicrobial agents: overview and conclusions, p. 527-535. In D. C. Hooper and J. S. Wolfson (ed.), Quinolone antimicrobial agents, 2nd ed. American Society for Microbiology, Washington, D.C.
23. National Committee for Clinical Laboratory Standards. 1994. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. National Committee for Clinical Laboratory Standards, Villanova, Pa.
24. Quale, J. M., D. Landman, and N. Mobarakai. 1994. Treatment of experimental endocarditis due to multidrug resistant Enterococcus faecium with ciprofloxacin and novobiocin. J. Antimicrob. Chemother. 34:797-802.
25. Ruoff, K. L. 1995. Streptococcus, p. 299-307. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
26. Tebas, P., R. Martinez Ruiz, F. Roman, P. Mendaza, J. C. Rodriquez Diaz, R. Daza, and J. Martinez L. de Letona. 1991. Early resistance to rifampicin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis. J. Infect. Dis. 163:204-205.
27. Van der Meer, J. T., W. van Vianen, E. Hu, W. B. van Leeuwen, H. A. van Valkenburg, J. Thompson, and M. F. Michel. 1991. Distribution, antibiotic susceptibility, and tolerance of bacterial isolates in culture-positive cases of endocarditis in The Netherlands. Eur. J. Clin. Microbiol. Infect. Dis. 10:728-734.
28. Whitman, M. S., P. G. Pitsakis, A. Zausner, L. L. Livornese, A. J. Osborne, C. C. Johnson, and M. E. Levison. 1993. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 37:2069-2073.
29. Wolfson, J. S., and D. C. Hooper. 1989. Fluoroquinolone antimicrobial agents. Clin. Microbiol. Rev. 2:378-424.
30. Zaman, M. M., D. Landman, S. Burney, and J. M. Quale. 1996. Treatment of experimental endocarditis due to multidrug-resistant Enterococcus faecium with clinafloxacin and penicillin. J. Antimicrob. Chemother. 37:127-132.